Brandywine Global Investment Management LLC Has $3.21 Million Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Brandywine Global Investment Management LLC trimmed its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 41.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 85,722 shares of the company’s stock after selling 60,482 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Harmony Biosciences were worth $3,208,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. lifted its stake in shares of Harmony Biosciences by 0.6% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock valued at $1,762,000 after buying an additional 298 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Harmony Biosciences by 1.2% in the third quarter. Thrivent Financial for Lutherans now owns 28,639 shares of the company’s stock valued at $789,000 after buying an additional 348 shares in the last quarter. Nebula Research & Development LLC lifted its stake in shares of Harmony Biosciences by 2.0% in the second quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock valued at $550,000 after buying an additional 348 shares in the last quarter. Profund Advisors LLC lifted its stake in shares of Harmony Biosciences by 5.1% in the third quarter. Profund Advisors LLC now owns 10,803 shares of the company’s stock valued at $298,000 after buying an additional 520 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Harmony Biosciences by 2.4% in the second quarter. The Manufacturers Life Insurance Company now owns 22,686 shares of the company’s stock valued at $717,000 after buying an additional 532 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HRMY shares. Deutsche Bank Aktiengesellschaft lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a research note on Monday, February 23rd. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright reiterated a “buy” rating on shares of Harmony Biosciences in a research note on Friday, May 22nd. Bank of America reduced their target price on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a research note on Wednesday, February 25th. Finally, Truist Financial boosted their price objective on shares of Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research note on Friday, May 8th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Harmony Biosciences currently has a consensus rating of “Hold” and a consensus target price of $40.89.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $35.48 on Thursday. The company has a 50 day moving average of $30.58 and a 200 day moving average of $33.12. The stock has a market cap of $2.05 billion, a P/E ratio of 14.31, a P/E/G ratio of 0.24 and a beta of 0.96. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.87. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The firm had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. During the same period in the prior year, the firm posted $0.78 EPS. Harmony Biosciences’s revenue was up 16.6% on a year-over-year basis. As a group, sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 3.2 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.